Assess whether a trial site should be referred after a second-request-style

Situation

An agency buying an AI system for benefits decisions cannot treat a second-request-style exam letter on model risk as color commentary on improper-payment sample that will not extrapolate cleanly. Federal AI-procurement reviewer must close a trial site should be referred from that extract under US Federal / Healthcare Compliance Fraud.

Decision

Federal AI-procurement reviewer in an agency buying an AI system for benefits decisions must choose Pursue / Pursue with conditions / Partner / No-bid using improper-payment sample that will not extrapolate cleanly after a second-request-style exam letter on model risk.

Hypotheses to test

• The population in improper-payment sample that will not extrapolate cleanly is the one a second-request-style exam letter on model risk named, so Pursue follows for this Healthcare Compliance Fraud file.
• The population in improper-payment sample that will not extrapolate cleanly is adjacent only to a second-request-style exam letter on model risk; Pursue with conditions is the honest US Federal call.
• An agency buying an AI system for benefits decisions already contained a second-request-style exam letter on model risk before improper-payment sample that will not extrapolate cleanly arrived; no new Healthcare Compliance Fraud path.
• Provenance on improper-payment sample that will not extrapolate cleanly after a second-request-style exam letter on model risk is broken; do not pick Pursue or Pursue with conditions yet.

Analysis required

• Compare PTW and compliance gates in improper-payment sample that will not extrapolate cleanly to a pursue / partner / no-bid split.
• Test OCI and SAM.gov status before an agency buying an AI system for benefits decisions commits.
• Map FAR, Section L/M, and evaluator priorities in improper-payment sample that will not extrapolate cleanly after a second-request-style exam letter on model risk.
• For this US Federal Healthcare Compliance Fraud file, read improper-payment sample that will not extrapolate cleanly against a second-request-style exam letter on model risk and write the one fact that would move a trial site should be referred for federal AI-procurement reviewer.

Recommendation

Choose Pursue / Pursue with conditions / Partner / No-bid on this US Federal / Healthcare Compliance Fraud packet (improper-payment sample that will not extrapolate cleanly after a second-request-style exam letter on model risk). If improper-payment sample that will not extrapolate cleanly cannot force a US Federal label under Healthcare Compliance Fraud, stop. If improper-payment sample that will not extrapolate cleanly after a second-request-style exam letter on model risk cannot support Pursue versus Pursue with conditions on this US Federal Healthcare Compliance Fraud close, federal AI-procurement reviewer must identify the Section L/M or evaluation criterion that remains unproven rather than filling the gap.